CN1582910A - Calcium phenol sulfonate dispersive tablets and their preparation - Google Patents
Calcium phenol sulfonate dispersive tablets and their preparation Download PDFInfo
- Publication number
- CN1582910A CN1582910A CN 200410042865 CN200410042865A CN1582910A CN 1582910 A CN1582910 A CN 1582910A CN 200410042865 CN200410042865 CN 200410042865 CN 200410042865 A CN200410042865 A CN 200410042865A CN 1582910 A CN1582910 A CN 1582910A
- Authority
- CN
- China
- Prior art keywords
- parts
- agent
- disintegrating agent
- dispersible tablet
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 8
- JVEDXKIOAFPPPG-UHFFFAOYSA-L calcium;4-hydroxybenzenesulfonate Chemical compound [Ca+2].OC1=CC=C(S([O-])(=O)=O)C=C1.OC1=CC=C(S([O-])(=O)=O)C=C1 JVEDXKIOAFPPPG-UHFFFAOYSA-L 0.000 title 1
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims abstract description 44
- 229960005438 calcium dobesilate Drugs 0.000 claims abstract description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000741 silica gel Substances 0.000 claims abstract description 16
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000007919 dispersible tablet Substances 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 239000008187 granular material Substances 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 25
- 239000011575 calcium Substances 0.000 claims description 25
- 229910052791 calcium Inorganic materials 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 23
- WHOZNOZYMBRCBL-OUKQBFOZSA-N (2E)-2-Tetradecenal Chemical compound CCCCCCCCCCC\C=C\C=O WHOZNOZYMBRCBL-OUKQBFOZSA-N 0.000 claims description 20
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 20
- 229940044654 phenolsulfonic acid Drugs 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 18
- 229920002472 Starch Polymers 0.000 claims description 16
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 16
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 16
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 235000019698 starch Nutrition 0.000 claims description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000000080 wetting agent Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 12
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical class OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004137 mechanical activation Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
The phenolsulfonic acid calcium dispersible tablet | Calcium dobesilate | |
Specification | 0.25g | 0.5g |
Outward appearance | The off-white color sheet, unilateral bright clean | The off-white color sheet, unilateral coarse |
Disintegration | Just disintegrate is complete in the time of 1 minute, and the granule after the disintegrate all can be by 24 sieves. | Disintegrate in 15 minutes |
Friability | 0.3%, the sheet of non-cracking, be full of cracks and pulverizing | Greater than 1.0%, and the slice, thin piece fragmentation is arranged |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410042865 CN1259042C (en) | 2004-05-28 | 2004-05-28 | Calcium phenol sulfonate dispersive tablets and their preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410042865 CN1259042C (en) | 2004-05-28 | 2004-05-28 | Calcium phenol sulfonate dispersive tablets and their preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1582910A true CN1582910A (en) | 2005-02-23 |
CN1259042C CN1259042C (en) | 2006-06-14 |
Family
ID=34601686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410042865 Expired - Lifetime CN1259042C (en) | 2004-05-28 | 2004-05-28 | Calcium phenol sulfonate dispersive tablets and their preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1259042C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100377705C (en) * | 2005-11-03 | 2008-04-02 | 上海朝晖药业有限公司 | Calcium hydrophenyl sulfonate capsule and its prepn process |
CN104644587A (en) * | 2015-03-20 | 2015-05-27 | 王雪雁 | Preparation method of medicine composition for treating cardiovascular disease |
CN108272763A (en) * | 2018-03-29 | 2018-07-13 | 海南林恒制药股份有限公司 | A kind of Calcium Dobsilate and preparation method thereof |
-
2004
- 2004-05-28 CN CN 200410042865 patent/CN1259042C/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100377705C (en) * | 2005-11-03 | 2008-04-02 | 上海朝晖药业有限公司 | Calcium hydrophenyl sulfonate capsule and its prepn process |
CN104644587A (en) * | 2015-03-20 | 2015-05-27 | 王雪雁 | Preparation method of medicine composition for treating cardiovascular disease |
CN108272763A (en) * | 2018-03-29 | 2018-07-13 | 海南林恒制药股份有限公司 | A kind of Calcium Dobsilate and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1259042C (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1805738A (en) | Extended-release tablets of metformin | |
KR20120117985A (en) | Dry-coated orally disintegrating tablet | |
CN1823091A (en) | Functional starch powder | |
JP3534130B2 (en) | Pharmaceutical composition | |
KR20040005986A (en) | Solid Pharmaceutical Formulations Comprising Modafinil | |
CN101612135A (en) | A kind of levetiracetam composition and method of making the same that is used for direct compression | |
CN104042580B (en) | A kind of valsartan dispersible tablet and preparation method thereof | |
CN1613442A (en) | Disintegrants for deodoring effectively and their preparation | |
CN104706640B (en) | A kind of Pharmaceutical composition and its preparation technology containing Irbesartan | |
TWI316406B (en) | Novel pharmaceutical formulations of modafinil | |
CN102526748B (en) | Oral tablet containing Valsartan, Hydrochioro and Amlodipine Besylate Tablet | |
CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
CN1259042C (en) | Calcium phenol sulfonate dispersive tablets and their preparation | |
CN1903208A (en) | Adefovir dipivoxil oral disintegration tablets medicine prepn., and prepn. method therefor | |
CN1864679A (en) | A composite bergenin dispersible tablet and preparation method thereof | |
JP4774739B2 (en) | Kampo extract-containing tablet composition and method for producing the same | |
CN102198107B (en) | Lacidipine dispersible tablets and preparation method thereof | |
CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
CN101711753B (en) | Preparation method of lansoprazole solid preparation | |
CN114129524A (en) | Paracetamol tablet and preparation method thereof | |
CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
CN1634014A (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
CN1528273A (en) | Analgesic tramadol hydrochloride oral disintegrating tablet and preparing method thereof | |
CN1296045C (en) | Oral disintegration tablet of dihydroergotoxine and its derivatives and its preparing process | |
CN1509711A (en) | Fenfibrate masticatory and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU WANGAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XU XINSHENG; WEN YANQIU Effective date: 20060804 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060804 Address after: 226100 Haimen Road, 688, economic and Technological Development Zone, Haimen, Jiangsu Patentee after: JIANGSU WANGAO PHARMACEUTICAL CO.,LTD. Address before: Four Beijing 100012 Chaoyang District City Beiyuan No. five hospital (Beijing Institute of geology research building) Co-patentee before: Wen Yanqiu Patentee before: Xu Xinsheng |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 226100 Haimen Road, 688, economic and Technological Development Zone, Haimen, Jiangsu Patentee after: Jiangsu Wangao Pharmaceutical Co.,Ltd. Address before: 226100 Haimen Road, 688, economic and Technological Development Zone, Haimen, Jiangsu Patentee before: JIANGSU WANGAO PHARMACEUTICAL CO.,LTD. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060614 |